Apricoxib

Source: Wikipedia, the free encyclopedia.
Apricoxib
Legal status
Legal status
  • Investigational
Identifiers
  • 4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide
JSmol)
  • CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C
  • InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23)
  • Key:JTMITOKKUMVWRT-UHFFFAOYSA-N

Apricoxib is an experimental anticancer drug and

COX-2 inhibitor which is intended to improve standard therapy response in molecularly-defined models of pancreatic cancer.[2] It was also studied in clinical trials for non-small-cell lung cancer.[3] Development was abandoned in 2015 due to poor clinical trial results.[4]

See also

References

  1. ^ "Apricoxib (Code C74021)". NCI Thesaurus. National Cancer Institute.
  2. PMID 22829202
    .
  3. .
  4. ^ "Apricoxib". Adis Insight. Springer Nature Switzerland AG.